	US 11,999,787 B2
	Tie2-binding agents and methods of use
Minhong Yan, Foster City, CA (US); Gu Zhang, Millbrae, CA (US); Nicholas John Agard, San Francisco, CA (US); Danielle Marie Dicara, San Francisco, CA (US); Philip E. Hass, Moss Beach, CA (US); Julie Q. Hang, San Jose, CA (US); Erin L. Christensen, Corte Madera, CA (US); Robert Paul Morse, San Diego, CA (US); Sarah Sanowar, San Francisco, CA (US); and Vittal Shivva, Foster City, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Mar. 22, 2021, as Appl. No. 17/208,292.
Claims priority of provisional application 63/046,318, filed on Jun. 30, 2020.
Claims priority of provisional application 62/993,930, filed on Mar. 24, 2020.
Prior Publication US 2021/0332142 A1, Oct. 28, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/60 (2017.01); A61K 47/68 (2017.01); A61P 27/02 (2006.01)

CPC C07K 16/2863 (2013.01) [A61K 9/0048 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61K 47/6849 (2017.08); A61P 27/02 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)]

30 Claims

1. A conjugate that binds to Tie2, wherein the conjugate comprises two, three, four, five, six, seven, or eight antibodies or antigen-binding fragments thereof, wherein each of the antibodies or fragments thereof bind Tie2 and comprises:

a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence NTDIS (SEQ ID NO:3), (b) CDR-H2 comprising the amino acid sequence RISPSDGNTYYADSVKG (SEQ ID NO:4), and (c) CDR-H3 comprising the amino acid sequence RTRWASWAFDY (SEQ ID NO:7), and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO:8), (e) CDR-L2 comprising the amino acid sequence SASFLYS (SEQ ID NO:9), and (f) CDR-L3 comprising the amino acid sequence QQSYTTPPT (SEQ ID NO:10), and

wherein each of the antibodies or antigen-binding fragment thereof is linked to a multimerizing moiety.